Purple Biotech
Purple Biotech
PPBT
NASDAQ
2.66
USD
-1.48%
About
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways.
The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 184.9K |
| Three Month Average Volume | 6.0M |
| High Low | |
| Fifty-Two Week High | 1.8 USD |
| Fifty-Two Week Low | 0.3023 USD |
| Fifty-Two Week High Date | 23 Oct 2023 |
| Fifty-Two Week Low Date | 16 Apr 2024 |
| Price and Volume | |
| Current Price | 0.489 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 26.05% |
| Thirteen Week Relative Price Change | -43.42% |
| Twenty-Six Week Relative Price Change | -51.55% |
| Fifty-Two Week Relative Price Change | -67.75% |
| Year-to-Date Relative Price Change | -47.06% |
| Price Change | |
| One Day Price Change | 6.30% |
| Thirteen Week Price Change | -39.44% |
| Twenty-Six Week Price Change | -46.73% |
| Five Day Price Change | 22.26% |
| Fifty-Two Week Price Change | -59.59% |
| Year-to-Date Price Change | -37.31% |
| Month-to-Date Price Change | 26.78% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.35538 USD |
| Book Value Per Share (Most Recent Quarter) | 1.12917 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.2442 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.10833 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.79169 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.7877 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.7402 USD |
| Normalized (Last Fiscal Year) | -0.7877 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.7877 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.7402 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.7877 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.7402 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.61067 USD |
| Cash Per Share (Most Recent Quarter) | 0.3951 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.78366 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.68966 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.70027 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 43.55% |
| EPS Change (Trailing Twelve Months) | 28.57% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 5 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -10,547,000 |
| Net Debt (Last Fiscal Year) | -15,061,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -19,928,000 |
| Free Cash Flow (Trailing Twelve Months) | -18,943,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1 |
| Total Debt to Equity (Most Recent Quarter) | 1 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -40.39% |
| Return on Assets (Trailing Twelve Months) | -40.57% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -49.02% |
| Return on Equity (Trailing Twelve Months) | -48.17% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -47.34% |
| Return on Investment (Trailing Twelve Months) | -47.99% |
| Return on Investment (5 Year) | -99,999.99% |